IDE requested for "self-growing" heart valve:
This article was originally published in Clinica
Executive Summary
CryoLife has submitted an investigational device exemption (IDE) application to the FDA to begin US trials of its SynerGraft tissue-engineered pulmonary heart valve, intended for children. The product is a collagen frame based on a porcine valve from which the cells have been removed. Animal studies show that the frame is re-populated by the recipient's own cells and grows as the recipient grows. Six Australian adults already have SynerGraft implants and all are "doing well", says the Atlanta, Georgia-based company. It hopes the US trials will recruit up to 150 pediatric patients. Meanwhile European regulators are considering the product for CE-marking, the company claims.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.